[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @financebully financebully financebully posts on X about $arvn, $crvs, $nams, $pfe the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1331729246851567618/interactions)  - X Week XXXXXX +183% - X Month XXXXXX -XXXX% - X Months XXXXXX +222% - X Year XXXXXXX +741% ### Mentions: XX [#](/creator/twitter::1331729246851567618/posts_active)  - X Week XX +56% - X Month XXX +11% - X Months XXX +94% - X Year XXX +318% ### Followers: XXX [#](/creator/twitter::1331729246851567618/followers)  - X Week XXX +2.30% - X Month XXX +7.20% - X Months XXX +36% - X Year XXX +23% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1331729246851567618/influencer_rank)  ### Social Influence [#](/creator/twitter::1331729246851567618/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [finance](/list/finance) XXXX% [technology brands](/list/technology-brands) XXXX% [currencies](/list/currencies) XXXX% **Social topic influence** [$arvn](/topic/$arvn) #2, [$crvs](/topic/$crvs) 2.08%, [$nams](/topic/$nams) 1.04%, [$pfe](/topic/$pfe) #71, [investment](/topic/investment) 1.04%, [$ptgx](/topic/$ptgx) 1.04%, [$atai](/topic/$atai) #22, [$abvx](/topic/$abvx) #28, [$olma](/topic/$olma) #1, [$12m](/topic/$12m) XXXX% **Top accounts mentioned or mentioned by** [@wallstsai](/creator/undefined) [@hothomaswphelps](/creator/undefined) [@semodough](/creator/undefined) [@pjamess69](/creator/undefined) [@doepkemichel](/creator/undefined) [@tradingsssss](/creator/undefined) [@houndcl](/creator/undefined) [@madrigalpharma](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@jabroni16](/creator/undefined) [@pfizer](/creator/undefined) [@bioinvestor24](/creator/undefined) [@jfais20](/creator/undefined) [@cangermayer](/creator/undefined) [@grok](/creator/undefined) [@bananaoncology](/creator/undefined) [@cjkb117](/creator/undefined) [@microcapreturns](/creator/undefined) [@bambossie81](/creator/undefined) [@goldmansachs](/creator/undefined) **Top assets mentioned** [Arvinas, Inc (ARVN)](/topic/$arvn) [NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)](/topic/$nams) [Pfizer, Inc. (PFE)](/topic/$pfe) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx) [ATAI Life Sciences (ATAI)](/topic/$atai) [GSK plc (GSK)](/topic/$gsk) [Synthetify (SNY)](/topic/$sny) [Insmed, Inc. (INSM)](/topic/$insm) [AstraZeneca PLC (AZN)](/topic/$azn) [Eli Lilly and Company (LLY)](/topic/$lly) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Johnson & Johnson (JNJ)](/topic/$jnj) ### Top Social Posts [#](/creator/twitter::1331729246851567618/posts) --- Top posts by engagements in the last XX hours "@PersimmonTI i'm not sure if they will be the next but i've been bullish on $nams for several months now after broadway study suggested mace benefit and more recently the ptau217 data. huge added benefit over other treatments in the space. + very strong team/bod" [X Link](https://x.com/financebully/status/1977749590922162262) [@financebully](/creator/x/financebully) 2025-10-13T14:53Z XXX followers, XXX engagements "$arvn 2024 bod comp @JohnGHouston: $12m briggs morrison: $441k edward kennedy: $423k everett cunningham: $425k john young: $422k laurie smaldone-alsup: $430k leslie norwalk: $425k linda bain: $435k sunil agarwal: $785k timothy shannon: $416k wendy dixon: $425k @ArvinasInc" [X Link](https://x.com/financebully/status/1968440290374524995) [@financebully](/creator/x/financebully) 2025-09-17T22:21Z XXX followers, XXX engagements "@tradingsssss exactly. they're invested in many stocks. so funny that folks use this as a data point to justify an investment. i own $pali and $crvs but could care less which biotech funds are invested in them. they pick both winners and losers just like the rest of us" [X Link](https://x.com/financebully/status/1975916418467323917) [@financebully](/creator/x/financebully) 2025-10-08T13:29Z XXX followers, XXX engagements "@adamfeuerstein even crazier is that the current ceo of monopar originally developed the drug as an undergrad at northwestern. he founded the company (wilson therapeutics) that was acquired by alexion (then by az). then the drug was later licensed by monopar back in the hands of developer" [X Link](https://x.com/financebully/status/1976251284857762284) [@financebully](/creator/x/financebully) 2025-10-09T11:39Z XXX followers, 1519 engagements "@HOThomasWPhelps keep in mind that $ptgx already had good ph2 data from their second clinical stage asset rusfertide by this time. but agree that $crvs soq is good value at current mc" [X Link](https://x.com/financebully/status/1976727610068488593) [@financebully](/creator/x/financebully) 2025-10-10T19:12Z XXX followers, XXX engagements "@PersimmonTI this meta-analysis of prior ph3 studies bodes well for likelihood of prevail sucess. $nams" [X Link](https://x.com/financebully/status/1977750752631124212) [@financebully](/creator/x/financebully) 2025-10-13T14:58Z XXX followers, XXX engagements "@HOThomasWPhelps ive been listening. great background to the itk challenges of the past. have to assume $crvs likely has more potent molecules in preclinical development" [X Link](https://x.com/financebully/status/1978085206583103831) [@financebully](/creator/x/financebully) 2025-10-14T13:07Z XXX followers, XXX engagements "@herostick $25m (including wind down costs) vs $30m (near term milestones) seems like a big win for this company/molecule. not sure why $gsk doesn't just acquire $scyx ($34m mc -$8m ev) at this point though. $150-200m and they're done" [X Link](https://x.com/financebully/status/1978450456142651426) [@financebully](/creator/x/financebully) 2025-10-15T13:18Z XXX followers, XXX engagements "$atai bpl-003 btd. steady build" [X Link](https://x.com/financebully/status/1978925082777960709) [@financebully](/creator/x/financebully) 2025-10-16T20:44Z XXX followers, XXX engagements "tepi was just awarded a fda priority review voucher. $sny invested in $sabs developing a novel approach to t1d treatment. 🤔" [X Link](https://x.com/financebully/status/1978939570071666992) [@financebully](/creator/x/financebully) 2025-10-16T21:42Z XXX followers, XXX engagements "@monaco_biotech $130m - seems like they should've raised more but happy with their judicious use of funds so far. @SriniGRao @C_Angermayer why announce the same day of btd news though retail/tutes are slow - they can only handle one news announcement at a time. $atai" [X Link](https://x.com/financebully/status/1979148802201133336) [@financebully](/creator/x/financebully) 2025-10-17T11:33Z XXX followers, XXX engagements "@doepke_michel unlikely to buy $abvx too. they wouldn't want to compete with ico. i think $abvx deserves another partner" [X Link](https://x.com/financebully/status/1978165104920207462) [@financebully](/creator/x/financebully) 2025-10-14T18:24Z XXX followers, XXX engagements "@haodongvli $insm is overvalued atm so i'd be surprised if they could find a buyer. i think it would be wise for $ptgx to sell as long as its a fair value of not just their lead programs but also their clinically validate platform and pipeline" [X Link](https://x.com/financebully/status/1977830736209346583) [@financebully](/creator/x/financebully) 2025-10-13T20:16Z XXX followers, XXX engagements "@jfais20 $kura ev is only $250m w/ a likely upcoming lead asset approval which would trigger additional milestone payments. i'm sticking with this one. glta" [X Link](https://x.com/financebully/status/1978422337230766461) [@financebully](/creator/x/financebully) 2025-10-15T11:26Z XXX followers, XXX engagements "@semodough in addition to $crvs i've also started a position in $acrs given their earlier itk selective pipeline. if soquelitinib hits this is a market large enough to support a number of itk inhibitors assuming their just as or more effective and safe than dupi" [X Link](https://x.com/financebully/status/1978853239329067321) [@financebully](/creator/x/financebully) 2025-10-16T15:59Z XXX followers, XXX engagements "@ByMadeleineA I assume theyll want contribution of components Seems short sighted that $pfe gave up given the others are clearly fudging their numbers with more favorable patient population. $arvn" [X Link](https://x.com/financebully/status/1979478632423645187) [@financebully](/creator/x/financebully) 2025-10-18T09:24Z XXX followers, XXX engagements "@seedy19tron @Andre_AGTC @WallStSai don't short $celc brian sullivan. ;) roche data is bs - mutESR1 population is likely driving the benefit in the itt group. after $arvn data i don't see any serd winning in itt including $olma unless they fudge data by more favorable pt population" [X Link](https://x.com/financebully/status/1979577507788841389) [@financebully](/creator/x/financebully) 2025-10-18T15:57Z XXX followers, XXX engagements "@BianchiniGP @myESMO just like the rest of the serds and degraders $arvn $olma $lly $rhhby $azn" [X Link](https://x.com/financebully/status/1979642722911936874) [@financebully](/creator/x/financebully) 2025-10-18T20:16Z XXX followers, XXX engagements "$idya looks to be on par with zai lab zl-1310 but impressive nonetheless. 💥" [X Link](https://x.com/financebully/status/1964715270041412022) [@financebully](/creator/x/financebully) 2025-09-07T15:39Z XXX followers, 1518 engagements "@wyv_123 youre missing tremfya in your bar graph. $jnj is not buying $abvx" [X Link](https://x.com/financebully/status/1979801000568610972) [@financebully](/creator/x/financebully) 2025-10-19T06:45Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@financebully financebully
financebully posts on X about $arvn, $crvs, $nams, $pfe the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +183%
- X Month XXXXXX -XXXX%
- X Months XXXXXX +222%
- X Year XXXXXXX +741%
Mentions: XX #
- X Week XX +56%
- X Month XXX +11%
- X Months XXX +94%
- X Year XXX +318%
Followers: XXX #
- X Week XXX +2.30%
- X Month XXX +7.20%
- X Months XXX +36%
- X Year XXX +23%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXX% finance XXXX% technology brands XXXX% currencies XXXX%
Social topic influence $arvn #2, $crvs 2.08%, $nams 1.04%, $pfe #71, investment 1.04%, $ptgx 1.04%, $atai #22, $abvx #28, $olma #1, $12m XXXX%
Top accounts mentioned or mentioned by @wallstsai @hothomaswphelps @semodough @pjamess69 @doepkemichel @tradingsssss @houndcl @madrigalpharma @adamfeuerstein @jabroni16 @pfizer @bioinvestor24 @jfais20 @cangermayer @grok @bananaoncology @cjkb117 @microcapreturns @bambossie81 @goldmansachs
Top assets mentioned Arvinas, Inc (ARVN) NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Pfizer, Inc. (PFE) Protagonist Therapeutics, Inc (PTGX) ATAI Life Sciences (ATAI) GSK plc (GSK) Synthetify (SNY) Insmed, Inc. (INSM) AstraZeneca PLC (AZN) Eli Lilly and Company (LLY) IDEAYA Biosciences, Inc. Common Stock (IDYA) Johnson & Johnson (JNJ)
Top Social Posts #
Top posts by engagements in the last XX hours
"@PersimmonTI i'm not sure if they will be the next but i've been bullish on $nams for several months now after broadway study suggested mace benefit and more recently the ptau217 data. huge added benefit over other treatments in the space. + very strong team/bod"
X Link @financebully 2025-10-13T14:53Z XXX followers, XXX engagements
"$arvn 2024 bod comp @JohnGHouston: $12m briggs morrison: $441k edward kennedy: $423k everett cunningham: $425k john young: $422k laurie smaldone-alsup: $430k leslie norwalk: $425k linda bain: $435k sunil agarwal: $785k timothy shannon: $416k wendy dixon: $425k @ArvinasInc"
X Link @financebully 2025-09-17T22:21Z XXX followers, XXX engagements
"@tradingsssss exactly. they're invested in many stocks. so funny that folks use this as a data point to justify an investment. i own $pali and $crvs but could care less which biotech funds are invested in them. they pick both winners and losers just like the rest of us"
X Link @financebully 2025-10-08T13:29Z XXX followers, XXX engagements
"@adamfeuerstein even crazier is that the current ceo of monopar originally developed the drug as an undergrad at northwestern. he founded the company (wilson therapeutics) that was acquired by alexion (then by az). then the drug was later licensed by monopar back in the hands of developer"
X Link @financebully 2025-10-09T11:39Z XXX followers, 1519 engagements
"@HOThomasWPhelps keep in mind that $ptgx already had good ph2 data from their second clinical stage asset rusfertide by this time. but agree that $crvs soq is good value at current mc"
X Link @financebully 2025-10-10T19:12Z XXX followers, XXX engagements
"@PersimmonTI this meta-analysis of prior ph3 studies bodes well for likelihood of prevail sucess. $nams"
X Link @financebully 2025-10-13T14:58Z XXX followers, XXX engagements
"@HOThomasWPhelps ive been listening. great background to the itk challenges of the past. have to assume $crvs likely has more potent molecules in preclinical development"
X Link @financebully 2025-10-14T13:07Z XXX followers, XXX engagements
"@herostick $25m (including wind down costs) vs $30m (near term milestones) seems like a big win for this company/molecule. not sure why $gsk doesn't just acquire $scyx ($34m mc -$8m ev) at this point though. $150-200m and they're done"
X Link @financebully 2025-10-15T13:18Z XXX followers, XXX engagements
"$atai bpl-003 btd. steady build"
X Link @financebully 2025-10-16T20:44Z XXX followers, XXX engagements
"tepi was just awarded a fda priority review voucher. $sny invested in $sabs developing a novel approach to t1d treatment. 🤔"
X Link @financebully 2025-10-16T21:42Z XXX followers, XXX engagements
"@monaco_biotech $130m - seems like they should've raised more but happy with their judicious use of funds so far. @SriniGRao @C_Angermayer why announce the same day of btd news though retail/tutes are slow - they can only handle one news announcement at a time. $atai"
X Link @financebully 2025-10-17T11:33Z XXX followers, XXX engagements
"@doepke_michel unlikely to buy $abvx too. they wouldn't want to compete with ico. i think $abvx deserves another partner"
X Link @financebully 2025-10-14T18:24Z XXX followers, XXX engagements
"@haodongvli $insm is overvalued atm so i'd be surprised if they could find a buyer. i think it would be wise for $ptgx to sell as long as its a fair value of not just their lead programs but also their clinically validate platform and pipeline"
X Link @financebully 2025-10-13T20:16Z XXX followers, XXX engagements
"@jfais20 $kura ev is only $250m w/ a likely upcoming lead asset approval which would trigger additional milestone payments. i'm sticking with this one. glta"
X Link @financebully 2025-10-15T11:26Z XXX followers, XXX engagements
"@semodough in addition to $crvs i've also started a position in $acrs given their earlier itk selective pipeline. if soquelitinib hits this is a market large enough to support a number of itk inhibitors assuming their just as or more effective and safe than dupi"
X Link @financebully 2025-10-16T15:59Z XXX followers, XXX engagements
"@ByMadeleineA I assume theyll want contribution of components Seems short sighted that $pfe gave up given the others are clearly fudging their numbers with more favorable patient population. $arvn"
X Link @financebully 2025-10-18T09:24Z XXX followers, XXX engagements
"@seedy19tron @Andre_AGTC @WallStSai don't short $celc brian sullivan. ;) roche data is bs - mutESR1 population is likely driving the benefit in the itt group. after $arvn data i don't see any serd winning in itt including $olma unless they fudge data by more favorable pt population"
X Link @financebully 2025-10-18T15:57Z XXX followers, XXX engagements
"@BianchiniGP @myESMO just like the rest of the serds and degraders $arvn $olma $lly $rhhby $azn"
X Link @financebully 2025-10-18T20:16Z XXX followers, XXX engagements
"$idya looks to be on par with zai lab zl-1310 but impressive nonetheless. 💥"
X Link @financebully 2025-09-07T15:39Z XXX followers, 1518 engagements
"@wyv_123 youre missing tremfya in your bar graph. $jnj is not buying $abvx"
X Link @financebully 2025-10-19T06:45Z XXX followers, XX engagements